Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adenosine Triphosphate Clear all
Completed Phase 2 Interventional Results available

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

NCT01072175
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

NCT05488431
View directory record Official record
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
Interventions
Bempedoic acid, Placebo
Drug · Other
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
40 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 6, 2026, 5:24 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions

NCT01306994
View directory record Official record
Conditions
Arthrogryposis, Craniofacial Abnormalities
Interventions
Lactate, Glucose, and Adenosine Triphosphate Blood Levels, Physiological Stress Test, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, Observational Gait Analysis, Mental Health Interview
Other · Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Muscle Afferent Feedback Effects in Patients With Heart Failure

NCT01919918
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Muscle Contraction with Metabolite Solution Administration
Drug
Lead sponsor
University of Utah
Other
Eligibility
20 Years to 79 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Allopurinol in Heart Failure

NCT00181155
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

NCT00014248
View directory record Official record
Conditions
Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
adenosine triphosphate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

NCT02987959
View directory record Official record
Conditions
Soft-tissue Sarcoma
Interventions
TAK-228
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

NCT03685721
View directory record Official record
Conditions
Sickle Cell, PKLR Variants, Adenosine Triphosphate Activities
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

NCT01855373
View directory record Official record
Conditions
Blood Sugar, Endothelial Function
Interventions
PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo
Dietary Supplement · Other
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 6, 2026, 5:24 AM EDT
Not listed Phase 3 Interventional

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Azathioprine
Biological · Drug
Lead sponsor
Gastroenterology Research of America
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mendelian Reverse Cholesterol Transport Study

NCT01782027
View directory record Official record
Conditions
Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions
3H-cholesterol bound to albumin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

NCT06112990
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
creatine monohydrate, Placebo, Home-based, telehealth
Dietary Supplement · Other · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

NCT03738943
View directory record Official record
Conditions
Receptor Blockade
Interventions
Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated No phase listed Observational

Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions

NCT01307475
View directory record Official record
Conditions
Arthrogryposis, Craniofacial Abnormalities, Posttraumatic Stress Disorder, Depressive Disorder
Interventions
PTSD Checklist-Specific, Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, PTSD, Depression, and FSS-Focused Examination, Freeman-Sheldon Specific Quality of Life Survey, Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Other
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

NCT02626507
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Faslodex, Palbociclib, Zoladex
Drug
Lead sponsor
Hoffman Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 6, 2026, 5:24 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

NCT03972683
View directory record Official record
Conditions
Vasoconstriction, Vasodilation
Interventions
Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside
Other · Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional Results available

M3541 in Combination With Radiotherapy in Solid Tumors

NCT03225105
View directory record Official record
Conditions
Solid Tumors
Interventions
M3541, Palliative Radiotherapy (RT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 6, 2026, 5:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance & Optical Spectroscopy Validation

NCT01827527
View directory record Official record
Conditions
Validation Studies, Magnetic Resonance Spectroscopy
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of PeakATP on Mood, Reaction Time and Cognition

NCT05100589
View directory record Official record
Conditions
Cognitive Change, Mood
Interventions
PeakATP, Placebo
Dietary Supplement
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

NCT03662516
View directory record Official record
Conditions
Healthy Females
Interventions
PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

NCT03675893
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Letrozole, Abemaciclib, LY3023414, Metformin, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 6, 2026, 5:24 AM EDT